SCNI — Scinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: IL
- Exchange: NASDAQ
- Employees: 31
- Website: https://www.scinai.com
Latest SEC filings for SCNI
- 6-K — 2026-10-20
- 6-K — 2026-10-16
- 6-K — 2026-10-15
- 6-K — 2026-10-13
- EFFECT — 2026-10-06
- F-1 — 2026-09-24
- 6-K — 2026-09-21
- 6-K — 2026-09-08
- POS AM — 2026-08-27
- 6-K — 2026-08-26
Latest SCNI news
- — Scinai Immunotherapeutics announces $4M financing deal; shares tumble (seekingalpha_market)
- — Scinai Immunotherapeutics Announces $4.0 Million Financing Through a Private Placement and Warrant Inducement (prnewswire.com)
- — Committed customer orders at Scinai reach about $7.6 million, up about 300%. - Stock Titan (Stock Titan)
- — Scinai Expands CDMO Business with $5.1 Million Development and Clinical Manufacturing Agreement
- — Scinai Immunotherapeutics Ltd. SEC Filing (Oct 6, 2026) - Stock Titan (Stock Titan)
Educational tool only — not investment advice.